文献速递消化道肿瘤放疗

短程放疗序贯新辅助化疗治疗直肠腺癌的可行性及早期肿瘤学结局

Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma.
PubMed 文献 · Radiat Oncol · 2019-08-19

单中心回顾性分析26例局部晚期直肠腺癌患者,接受短程放疗(5 Gy×5次)序贯新辅助化疗(mFOLFOX6或卡培他滨联合奥沙利铂)后评估手术。81%完成全程化疗,19例治疗后内镜评估中9例达临床完全缓解(CCR),其中6例选择等待观察;主要放疗毒性为2级直肠炎(27%),术后30天内Clavien-Dindo 3级并发症6例(30%),无4-5级不良事件。

要点

  • 短程放疗序贯新辅助化疗耐受良好,临床完全缓解率和病理完全缓解率较高。
  • 81%患者完成全程新辅助化疗,19%因神经毒性等需减量。
  • 术后30天Clavien-Dindo 3级并发症发生率30%,无4-5级事件。

核心结论

  • 短程术前放疗序贯新辅助化疗耐受良好,肿瘤学结局优于短程放疗 alone 或长程放化疗的历史比较,临床和病理完全缓解率较高。

研究设计与样本

  • 单中心回顾性研究,纳入26例局部晚期直肠腺癌患者,均接受短程放疗(5 Gy×5次)序贯新辅助化疗后考虑手术。

主要发现

  • 26例中cT2 5例、cT3 16例、cT4 5例,88%为cN+。
  • 所有患者完成短程放疗,81%完成全程新辅助化疗,19%因毒性(最常见神经毒性)需减量。
  • 19例治疗后内镜评估中9例达临床完全缓解(CCR),其中6例选择等待观察。

关键数值与推荐

  • 短程放疗方案为5 Gy×5次。
  • 全程化疗定义为至少8周化疗。
  • mFOLFOX6一周期定义为两周。

临床怎么用

  • 短程放疗序贯新辅助化疗可作为局部晚期直肠腺癌术前治疗的可选策略,需关注神经毒性导致的化疗减量及术后并发症。
  • 达临床完全缓解的患者可考虑等待观察策略,但需个体化评估。

局限性

  • 单中心回顾性研究,样本量小(26例),缺乏对照组,结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is continued debate regarding the optimal combinations of radiation therapy and chemotherapy in the preoperative treatment of locally advanced rectal adenocarcinomas. We report our single-institution experience of feasibility and early oncologic outcomes of short-course preoperative radiation therapy (5 Gy X 5 fractions) followed by consolidation neoadjuvant chemotherapy. METHODS: We reviewed the records of 26 patients with locally advanced rectal adenocarcinoma. All patients underwent short course radiotherapy (5 Gy X 5 fractions) followed by chemotherapy [either modified infusional and bolus 5-fluorouracail and oxalipatin (mFOLFOX6) or capecitabine and oxaliplatin] prior to consideration for surgery. A full course of chemotherapy was defined as at least 8 weeks of chemotherapy. RESULTS: There were five clinical (c) T2, 16 cT3, and five cT4 rectal tumors, with 88% cN+. Twenty-five patients received a median of 4 cycles (range 3 to 8) of mFOLFOX6 (with one cycle defined as a two-week period); one patient received 3 cycles of capecitabine and oxaliplatin. All patients completed SCRT; 81% completed the full course of neoadjuvant chemotherapy with 19% requiring dose reductions in chemotherapy, most commonly due to neuropathy. Nineteen patients underwent post-treatment endoscopic evaluation, and nine patients were noted to achieve a complete clinical response (CCR). Six of the nine patients who achieved CCR opted for a non-operative approach of watch-and-wait. Twenty patients underwent surgical resection; pathologic complete response was observed in seven (35%) of these twenty. The main radiation-associated toxicity was proctitis with CTCAE Grade 2 proctitis observed in seven patients (27%). Post-operative Clavien-Dindo Grade 3 complications within 30 days of surgery were identified in six patients (30%), with no Grade 4 or 5 adverse events. Median length of hospital stay was 4.5 days (range 2-16 days); three patients were readmitted within a 30 day period. CONCLUSIONS: Short course preoperative radiotherapy followed by neoadjuvant chemotherapy was well-tolerated and achieved oncologic outcomes that compare favorably with short-course radiation therapy alone or long-course chemoradiotherapy. This regimen is associated with high rates of clinical and pathologic complete response.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jia AY, Narang A, Safar B, et al. Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma. Radiat Oncol. 2019. PMID: 31426827. doi:10.1186/s13014-019-1358-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。